Nail Unit Tumors: Mohs Surgery & Digit Preservation
Nail unit malignancies present unique diagnostic and surgical challenges due to the complex three-dimensional anatomy of the nail apparatus and the functional importance of digit preservation. Subungual squamous cell carcinoma (SCC) is the most common nail unit malignancy, with HPV (particularly types 16, 18, and 56) implicated in a substantial proportion of cases. Subungual melanoma, a variant of acral lentiginous melanoma, accounts for 0.7-3.5% of all melanomas and carries a poor prognosis partly due to delayed diagnosis. Mohs micrographic surgery offers a tissue-sparing alternative to amputation for selected nail unit tumors, with growing evidence supporting high cure rates and functional digit preservation. This article reviews the epidemiology, diagnosis, Mohs technique specifics, tissue processing, immunohistochemistry, and outcomes for nail unit malignancies.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-04-01·Updated: 2026-04-01·Reviewed: 2026-04-01
nail unit tumorssubungual SCCsubungual melanomaMohs surgerydigit preservationHPVlongitudinal melanonychianail matrix
Key Takeaways
- The nail unit is an NCCN H-zone; Mohs surgery is appropriate for all malignancies at this site regardless of size.
- Subungual SCC is the most common nail unit malignancy, with HPV detected in 60-80% of cases (types 16, 56).
- Mohs surgery for subungual SCC achieves 92-97% cure rates with functional digit preservation, avoiding amputation in the majority of patients.
- Subungual melanoma accounts for 15-35% of melanomas in darker-skinned populations. Melanoma in situ can be treated with Mohs + IHC (MART-1/SOX10) for digit-sparing cure.
- Always biopsy a nail lesion that fails to respond to treatment within 3-6 months. Average diagnostic delay for subungual SCC is 12-24 months.
- Preoperative radiographs are essential to assess for bone involvement, which may necessitate amputation rather than Mohs.
Overview & Epidemiology
Nail unit tumors encompass a spectrum of malignancies arising from the nail matrix, nail bed, hyponychium, and periungual skin. The nail apparatus is classified as an NCCN H-zone location, making Mohs surgery appropriate for virtually all malignancies at this site. Subungual SCC is the most common nail unit malignancy, accounting for approximately 55-75% of cases. It occurs predominantly in the fingernails (particularly the thumb and index finger) and has a strong association with high-risk HPV, especially types 16 and 56. The average delay from symptom onset to diagnosis is 12-24 months, often because early lesions mimic onychomycosis, warts, or chronic paronychia. Subungual melanoma is the second most common nail unit malignancy, representing 0.7-3.5% of all melanomas in white populations and 15-35% in darker-skinned populations. It most commonly affects the great toenail and the thumb. Other nail unit malignancies include keratoacanthoma (which can be locally aggressive and bone-destructive despite its typically self-limiting behavior elsewhere), Bowen disease (SCC in situ), and rarely, basal cell carcinoma, Merkel cell carcinoma, and metastatic deposits.
Nail Unit Anatomy for Mohs Surgery
Understanding the three-dimensional anatomy of the nail unit is essential for Mohs surgery at this site. The nail apparatus consists of four epithelial structures: the nail matrix (proximal and distal), the nail bed, the hyponychium, and the nail folds (proximal and lateral). The nail matrix is the germinative epithelium that produces the nail plate. It extends from the proximal nail fold to the lunula and wraps around the proximal phalanx in a U-shaped configuration. The proximal matrix produces the dorsal nail plate, while the distal matrix produces the ventral nail plate. Damage to the matrix results in permanent nail dystrophy or loss. The nail bed lies beneath the nail plate from the lunula to the hyponychium and is firmly adherent to the underlying periosteum. The thin nail bed epithelium lacks a granular layer, which distinguishes it from surrounding skin. The hyponychium is the epithelium beneath the free edge of the nail plate, forming the transition between the nail bed and the normal digital skin. The periosteum of the distal phalanx lies directly beneath the nail bed with minimal subcutaneous tissue, meaning that tumors invading through the nail bed can rapidly reach bone.
Surgical Planes & Tissue Layers
From superficial to deep, the surgical layers of the nail unit are: nail plate, nail bed epithelium (2-5 cell layers, no granular layer), dermis (thin, highly vascular, firmly adherent to periosteum), periosteum of the distal phalanx, and bone. The lack of subcutaneous fat between the nail bed and periosteum means that even superficially invasive tumors can involve periosteum earlier than expected. For Mohs surgery, the nail plate must be avulsed before tissue excision to allow access to the underlying nail bed and matrix. The surgeon must be aware that the matrix extends proximally beneath the proximal nail fold farther than is clinically apparent.
| Structure | Location | Function | Surgical Significance |
|---|---|---|---|
| Proximal nail matrix | Under proximal nail fold, extends to lunula | Produces dorsal nail plate | Damage causes permanent nail dystrophy. Tumor here requires careful dissection under the proximal nail fold. |
| Distal nail matrix | Visible as lunula | Produces ventral nail plate | Visible landmark for matrix extent. Excision here may still allow partial nail regrowth. |
| Nail bed | From lunula to hyponychium | Supports nail plate adherence | Thin epithelium directly over periosteum. Low threshold for bone involvement. |
| Hyponychium | Under free edge of nail plate | Seals the nail bed distally | Common site for subungual SCC extension. Include in margin assessment. |
| Lateral nail folds | Lateral edges of nail plate | Contains nail plate laterally | Periungual SCC/warts occur here. Lateral extent may be underestimated. |
| Periosteum | Over distal phalanx | Bone covering | Directly adherent to nail bed. Involvement may require bone curettage or partial amputation. |
Subungual Squamous Cell Carcinoma
Subungual SCC is the most common malignancy of the nail unit. It presents as chronic nail dystrophy, onycholysis, subungual hyperkeratosis, periungual swelling, or a non-healing periungual wound. The clinical mimicry of benign conditions (onychomycosis, verruca vulgaris, chronic paronychia, pyogenic granuloma) leads to an average diagnostic delay of 12-24 months. HPV DNA, particularly types 16 and 56, is detected in 60-80% of periungual and subungual SCC specimens, compared to less than 5% of non-acral cutaneous SCC. This high HPV prevalence suggests a distinct pathogenesis from UV-driven cutaneous SCC and may have implications for prognosis and prevention. Subungual SCC occurs predominantly on the fingers (thumb and index finger most common), with toenail involvement less frequent. The male-to-female ratio is approximately 2:1. Immunosuppressed patients (organ transplant recipients, HIV) have a markedly elevated risk.
| Feature | Subungual SCC | Verruca Vulgaris | Onychomycosis |
|---|---|---|---|
| Age | Typically >40 years | Any age, common in children | Typically >60 years |
| Digits affected | Thumb, index finger most common | Any digit, often multiple | Toenails > fingernails |
| Presentation | Chronic dystrophy, subungual mass, onycholysis | Verrucous papule, periungual | Distal onycholysis, subungual debris, yellow discoloration |
| Pain | Variable, often painless early | Usually painless | Usually painless |
| HPV association | 60-80% (HPV 16, 56) | 90%+ (HPV 2, 4, 27, 57) | None |
| Response to wart therapy | Poor or absent | Good (cryotherapy, salicylic acid) | N/A |
| Biopsy indication | Persistent lesion not responding to therapy | Atypical or refractory wart | Culture-negative dystrophy |
HPV-Associated Subungual SCC
The association between HPV and subungual SCC is well established and clinically relevant. HPV-positive subungual SCCs tend to present at a younger age and may have a somewhat lower risk of metastasis compared to HPV-negative tumors, analogous to the HPV-positive/negative distinction in oropharyngeal SCC. High-risk HPV types (16, 18, 31, 33, 56) are oncogenic through degradation of p53 and Rb tumor suppressor proteins by the viral E6 and E7 oncoproteins. Clinically, HPV-positive subungual SCC may have a verrucous or warty appearance that further mimics benign warts. The p16 immunohistochemical stain, a surrogate marker for high-risk HPV integration, can be used on biopsy specimens to support the diagnosis. HPV vaccination (9-valent Gardasil) covers types 16 and 18 but not type 56, which is a common subungual SCC-associated type.
Bowen Disease of the Nail Unit
Bowen disease (SCC in situ) of the nail unit is strongly HPV-associated and may present as chronic, refractory nail dystrophy, longitudinal erythronychia, or periungual hyperkeratosis. It is important to biopsy early, as Bowen disease can progress to invasive SCC if untreated. The clinical challenge is distinguishing Bowen disease from benign viral warts, onychomycosis, and lichen planus. HPV testing and p16 immunostaining can aid diagnosis. Treatment with Mohs surgery is appropriate and allows complete margin assessment with digit preservation. Alternatively, for patients who are not surgical candidates, topical 5-fluorouracil or photodynamic therapy have been reported with variable success rates.
Subungual Melanoma
Subungual melanoma is a variant of acral lentiginous melanoma (ALM) arising from the nail matrix. It accounts for 0.7-3.5% of all melanomas in white populations but represents 15-35% of melanomas in Black, Hispanic, and Asian populations, making it a critical diagnostic consideration in these groups. The most commonly affected digits are the great toenail (hallux) and the thumb. The classic presentation is longitudinal melanonychia (a pigmented band extending from the matrix to the free edge of the nail plate), though amelanotic variants account for up to 30% of cases and present as nail dystrophy, onycholysis, or a subungual mass. Hutchinson sign (periungual pigment extension onto the proximal or lateral nail folds) is a classic but not pathognomonic indicator of nail matrix melanoma. The prognosis of subungual melanoma is generally worse than that of non-acral melanoma of equivalent Breslow depth, partly due to diagnostic delay (average 1-3 years from onset to diagnosis) and partly due to the intrinsic biology of acral melanoma, which has a distinct mutational profile (KIT, NRAS, and BRAF non-V600E mutations rather than the BRAF V600E mutations common in truncal melanoma).
Diagnosis of Longitudinal Melanonychia
Longitudinal melanonychia (LM) is a pigmented band in the nail plate caused by melanin deposition from activated or proliferating nail matrix melanocytes. While LM is common in darker-skinned populations (present in up to 77% of Black adults), new or changing LM in any patient warrants evaluation. The ABCDEF rule for nail melanoma provides a clinical framework: Age (peak 5th-7th decade), Band (brown-black, >3mm wide, irregular borders), Change (rapid evolution in width or color), Digit (thumb > hallux > index finger), Extension (Hutchinson sign), and Family/personal history of melanoma. Dermoscopy of the nail plate (onychoscopy) can reveal irregular lines in color, spacing, thickness, and parallelism, features that distinguish malignant from benign melanonychia. A nail matrix biopsy is required for definitive diagnosis and should sample the origin of the pigmented band.
| Feature | Benign Melanonychia | Suspicious for Melanoma |
|---|---|---|
| Band color | Uniform brown, homogeneous | Brown-black, heterogeneous, irregular shades |
| Band width | Usually <3mm, stable | >3mm or progressively widening |
| Band borders | Regular, parallel lines | Irregular, loss of parallelism |
| Hutchinson sign | Absent | Pigment extends to proximal or lateral nail fold |
| Nail plate changes | Intact, normal texture | Dystrophy, splitting, or destruction |
| Patient age | Any (common in dark skin) | New onset in 5th-7th decade |
| Digit | Any, often multiple digits | Single digit: thumb, hallux, index |
Mohs Surgery Technique for Nail Unit Tumors
Mohs micrographic surgery for nail unit tumors requires specific technical modifications compared to standard cutaneous Mohs. The procedure begins with digital nerve block anesthesia and application of a digital tourniquet. The nail plate is then avulsed using a Freer elevator, separating it from the nail bed and matrix by advancing the instrument from proximal to distal. After nail plate removal, the tumor is visualized directly on the nail bed or matrix surface, and the first Mohs stage is excised with appropriate clinical margins. The specimen orientation is critical due to the complex three-dimensional anatomy. The lateral margins (nail folds), proximal margin (under the proximal nail fold), and deep margin (periosteum) must all be clearly identified and mapped. En face frozen sections are prepared, and the tissue is processed to allow examination of the entire peripheral and deep margins. The thin, adherent nature of nail bed tissue and the proximity to periosteum and bone make tissue processing technically demanding.
Tissue Processing Considerations
Frozen section processing of nail unit specimens presents several challenges. The nail bed epithelium is thin (2-5 cell layers) and firmly adherent to the underlying dermis and periosteum, making it difficult to flatten for en face sectioning. The nail matrix has a curved, U-shaped three-dimensional anatomy that does not lie flat in a single plane. Separation of the specimen into smaller pieces with careful orientation markings may be necessary. For melanoma, MART-1/MelanA and SOX10 immunohistochemistry on frozen sections is essential for margin assessment, as melanocytes are difficult to identify on routine H&E in the nail unit. For SCC, standard H&E is usually sufficient, but cytokeratin stains (AE1/AE3) can help delineate tumor from the thin nail bed epithelium. The use of rush permanent sections (formalin-fixed, paraffin-embedded) rather than frozen sections is advocated by some Mohs surgeons for nail unit melanoma, as permanent sections provide superior cellular detail for distinguishing atypical melanocytes from benign melanocytic activation.
Bone Involvement & Amputation Decisions
When Mohs surgery reveals tumor extending to periosteum, the surgeon must decide between periosteal curettage and amputation. For SCC confined to the periosteal surface without bone invasion, periosteal curettage with an additional Mohs stage to confirm clear margins may be sufficient, preserving digit length. Radiographic evidence of bone erosion or lytic changes on preoperative imaging generally indicates the need for partial amputation. For subungual melanoma, the depth of invasion (Breslow thickness) determines the extent of surgery. Melanoma in situ and thin invasive melanoma (Breslow <1mm) can often be managed with Mohs surgery and digit preservation. Thicker melanomas or those with bony invasion typically require amputation at the level of the DIP joint or more proximally, depending on the extent of disease.
Immunohistochemistry for Nail Unit Mohs
Immunohistochemistry (IHC) is frequently essential for Mohs surgery of nail unit tumors, particularly for melanoma. The standard panel for subungual melanoma margin assessment includes MART-1/MelanA, SOX10, and HMB-45. MART-1 provides excellent sensitivity for junctional melanocytes and is the most widely used stain for melanoma Mohs. SOX10 offers nuclear staining that can be easier to interpret than the cytoplasmic staining of MART-1, and it performs well on frozen sections. HMB-45 preferentially stains actively proliferating melanocytes and can help distinguish malignant melanocytes from benign melanocytic hyperplasia at the margins. PRAME (Preferentially Expressed Antigen in Melanoma) is an emerging marker that is positive in melanoma cells but negative in benign melanocytes, offering improved specificity for margin assessment. For SCC, IHC is less commonly needed, but cytokeratin stains (AE1/AE3, pankeratin) can help identify tumor strands in the thin nail bed epithelium, and p16 can serve as a surrogate marker for high-risk HPV integration.
| IHC Marker | Target | Staining Pattern | Use in Nail Unit Mohs |
|---|---|---|---|
| MART-1/MelanA | Melanocytic differentiation antigen | Cytoplasmic (brown) | Primary stain for melanoma margins. High sensitivity. Cannot distinguish benign from malignant melanocytes by staining alone. |
| SOX10 | Nuclear transcription factor | Nuclear (brown) | Melanoma margin assessment. Nuclear staining is easier to count and interpret than cytoplasmic MART-1. |
| HMB-45 | Melanosome-associated glycoprotein | Cytoplasmic (brown) | Adjunct stain. Preferentially stains actively proliferating melanocytes. Higher specificity than MART-1. |
| PRAME | Tumor-associated antigen | Nuclear/cytoplasmic | Emerging marker. Positive in melanoma, negative in benign melanocytes. Improves margin specificity. |
| p16 | CDK inhibitor (HPV surrogate) | Nuclear and cytoplasmic | Surrogate marker for high-risk HPV in subungual SCC. Supports HPV-driven pathogenesis. |
| AE1/AE3 | Pan-cytokeratin | Cytoplasmic | Highlights epithelial/SCC tumor cells in the thin nail bed epithelium. Useful for identifying subtle invasion. |
Other Nail Unit Malignancies
Beyond SCC and melanoma, several other malignancies can involve the nail unit. Keratoacanthoma (KA) of the nail unit (subungual KA) is a distinct entity that, unlike KA elsewhere on the body, does not spontaneously regress and can be locally destructive, eroding the distal phalanx. Subungual KA should be treated as a low-grade SCC and excised completely. Mohs surgery is appropriate for digit-sparing treatment. Basal cell carcinoma of the nail unit is exceedingly rare, with fewer than 50 reported cases in the literature. It presents as chronic nail dystrophy or a periungual nodule and is managed with Mohs surgery following the same principles as BCC elsewhere. Merkel cell carcinoma, dermatofibrosarcoma protuberans, and metastatic deposits to the distal phalanx have all been reported but are rare.
Reconstruction After Nail Unit Mohs
Reconstruction after Mohs surgery of the nail unit depends on the extent of tissue removal and the structures sacrificed. For small defects confined to the nail bed with preserved matrix, secondary intention healing over the intact periosteum often produces acceptable functional and cosmetic outcomes. The nail bed has excellent regenerative capacity, and granulation tissue fills nail bed defects effectively. When the nail matrix is partially excised, the remaining matrix may produce a narrowed but functional nail plate. Complete matrix excision results in permanent nail loss, and the wound bed is allowed to heal by secondary intention or covered with a full-thickness skin graft from the hypothenar eminence or medial arm. For defects extending to bone after periosteal curettage, healing by secondary intention is still possible and often preferred over grafting, as the granulation tissue contracts and epithelializes over 4-8 weeks. When amputation at the DIP joint is required, the wound is closed primarily. Patients should be counseled preoperatively about the range of possible outcomes, including permanent nail dystrophy or loss, altered sensation, and the small risk of requiring amputation if bone involvement is found intraoperatively.
Outcomes & Prognosis
Published outcomes for Mohs surgery of nail unit tumors demonstrate high cure rates with functional digit preservation. For subungual SCC, Mohs surgery achieves local cure rates of 92-97%, compared to 70-80% for standard excision and approximately 100% for amputation (which eliminates the anatomical substrate entirely). The recurrence rate after Mohs for subungual SCC is approximately 3-8%, and most recurrences are detected within the first 2 years. Metastatic rate for subungual SCC is low (approximately 2-5%), though it may be higher for deeply invasive or recurrent tumors. For subungual melanoma in situ, Mohs surgery with immunohistochemistry achieves margin clearance in over 95% of cases with digit preservation, avoiding the morbidity of amputation. For invasive subungual melanoma, the role of Mohs is more limited; thin invasive melanomas (Breslow <1mm) may be treated with Mohs, while thicker tumors generally require amputation. Five-year overall survival for subungual melanoma ranges from 16-80% depending on stage at diagnosis, highlighting the critical importance of early detection.
| Tumor Type | Treatment | Local Cure Rate | Digit Preservation | Recurrence Rate |
|---|---|---|---|---|
| Subungual SCC | Mohs surgery | 92-97% | Yes (majority) | 3-8% |
| Subungual SCC | Standard excision | 70-80% | Variable | 15-25% |
| Subungual SCC | Amputation | ~100% | No | <1% |
| Subungual melanoma in situ | Mohs + IHC | >95% | Yes | <5% |
| Subungual melanoma in situ | Amputation | ~100% | No | <1% |
| Invasive subungual melanoma (<1mm) | Mohs + IHC | 85-95% | Yes (selected cases) | 5-15% |
| Invasive subungual melanoma (>1mm) | Amputation | Depends on stage | No | Depends on stage |
Follow-Up & Surveillance
Patients treated with Mohs surgery for nail unit malignancies require structured follow-up tailored to the tumor type and risk level. For subungual SCC, clinical examination of the surgical site and regional lymph nodes every 3-6 months for the first 2 years, then every 6-12 months for years 3-5, is recommended. Most recurrences occur within the first 2 years. For subungual melanoma, follow-up is aligned with standard melanoma surveillance protocols based on AJCC stage: every 3-4 months for the first 2 years, every 6 months for years 3-5, then annually. Imaging (sentinel lymph node biopsy, PET/CT, MRI) is guided by stage and not routinely indicated for melanoma in situ. Patients should be educated on self-examination of the digit for signs of recurrence: new pigmentation, nail dystrophy, periungual mass, or lymphadenopathy. Full skin examination at each visit is important, as patients with one cutaneous malignancy are at elevated risk for second primary skin cancers.
Frequently Asked Questions
Related Articles
Recent Evidence
From the Northwestern Medicine Dermatologic Surgery Journal Club
Valdes Morales KL, Frankel D, Trifoi MD, et al. · Dermatologic Surgery (2025)
References
- [1]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
- [2]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous v1.2026. NCCN Guidelines. 2026.
- [3]Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.06.009 PMID: 22959232
- [4]El Tal AK, Abrou AE, Stiff MA, Mehregan DA. Immunostaining in Mohs micrographic surgery: a review. Dermatol Surg. 2010. PMID: 20100275
- [5]Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004. PMID: 15008870
- [6]Goldminz D, Bennett RG. Mohs micrographic surgery of the nail unit. J Dermatol Surg Oncol. 1992. doi:10.1111/j.1524-4725.1992.tb03004.x PMID: 1644945
- [7]Riddel C, Rashid R, Thomas V. Ungual and periungual human papillomavirus-associated squamous cell carcinoma: a review. J Am Acad Dermatol. 2011. doi:10.1016/j.jaad.2010.02.057 PMID: 21315482
- [8]Dika E, Piraccini BM, Balestri R, et al. Mohs surgery for squamous cell carcinoma of the nail: report of 15 cases. Our experience and a long-term follow-up. Br J Dermatol. 2012. doi:10.1111/j.1365-2133.2012.11129.x PMID: 22762413
- [9]de Berker D. Nail anatomy. Clin Dermatol. 2013. doi:10.1016/j.clindermatol.2013.06.006 PMID: 24079579
- [10]Dika E, Starace M, Patrizi A, et al. Mohs micrographic surgery for nail unit tumours: an update and a critical review of the literature. Dermatol Surg. 2018. doi:10.1097/DSS.0000000000001488 PMID: 29706031
- [11]Gou D, Nijhawan RI, Srivastava D. Mohs Micrographic Surgery as the Standard of Care for Nail Unit Squamous Cell Carcinoma. Dermatol Surg. 2020. doi:10.1097/DSS.0000000000002144 PMID: 31567588
- [12]Le M, Gabrielli S, Zloty D. Mohs Micrographic Surgery Is Equivalent to Nail Unit Excision or Amputation for Melanoma In Situ of the Nail Unit: A Systematic Review and Meta-Analysis. Dermatol Surg. 2023. doi:10.1097/DSS.0000000000003840 PMID: 37249515
- [13]Bray ER, Tosti A, Morrison BW. Update on Squamous Cell Carcinoma of the Nail Unit: An Human Papillomavirus-Associated Condition. Skin Appendage Disord. 2024. doi:10.1159/000537760 PMID: 38835716
- [14]Valdes Morales KL, Frankel D, Trifoi MD, et al. Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025. doi:10.1016/j.jaad.2024.11.078 PMID: 39848587
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program